Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people ...

Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, the Financial Times ...

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of ...

Rumors of a Revolution buyout come as the industry gears up for one of its biggest trade conferences, where observers expect ...

The U.S. now only recommends one dose of an HPV vaccine. It used to say all children should get two to three doses of the ...

Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a ...

Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines ...

RAHWAY, N.J. - Merck is officially adding an experimental flu prevention drug to its portfolio. The New Jersey-based ...

Jan 8 () - Merck is in talks to ​buy cancer drug developer ‌Revolution Medicines, the Financial Times ‌reported on Thursday, ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Merck & Co. is in talks to acquire the cancer-focused biotech company Revolution Medicines Inc., according to a report in the ...

Rising shares of Merck & Co. and Boeing Co. were helping turn around the Dow Jones Industrial Average in early trading. Drugmaker Merck saw its shares gain 2.5%, leading the blue-chip index higher ...